Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Assessing Virus Specific T Cell Responses in Patients of Ph-negative Myeloproliferative Neoplasms (MPN) Treated With Ruxolitinib

Next Previous
Trial Profile

Assessing Virus Specific T Cell Responses in Patients of Ph-negative Myeloproliferative Neoplasms (MPN) Treated With Ruxolitinib

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 23 Nov 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ruxolitinib (Primary)
  • Indications Essential thrombocythaemia; Myelofibrosis; Myeloproliferative disorders; Polycythaemia vera
  • Focus Adverse reactions

Most Recent Events

  • 01 Oct 2020 Results published in the Hematological Oncology
  • 05 Dec 2019 New trial record
  • 06 Nov 2019 Results (N=25), evaluating virus specific responses (viral load and T-cell response) in patients of myeloproliferative neoplasms (MPN) those who are treated with ruxolitinib, released at the 61st Annual Meeting and Exposition of the American Society of Hematology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top